Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: A suggested model of preventive strategy

Clinical Reviews in Allergy and Immunology

Volumn 44, Issue 1, 2013, Pages 14-22

  Bartoloni, Elena ^a   Alunno, Alessia ^a   Bistoni, Onelia ^a   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cardiovascular risk prevention; Subclinical atherosclerosis; Systemic autoimmune disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; INFLIXIMAB; METHOTREXATE; PIOGLITAZONE; PLACEBO; PREDNISONE; ROSIGLITAZONE;

ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PHYSICAL ACTIVITY; RHEUMATOID ARTHRITIS;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; RHEUMATIC DISEASES; RISK;

EID: 84872682897     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8251-x     Document Type: Article

References (67)

1. Holmqvist ME, Wedrén S, Jacobsson LTH et al (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis among patients diagnosed between 1995 and 2006. J Intern Med 268:578-585
2. Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337-3347 (Pubitemid 43739380)
3. Nurmohamed MT (2009) Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 8:663-667
4. Bartoloni Bocci E, Luccioli F, Angrisani C, Moscatelli S, Alunno A, Gerli R (2007) Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. Expert Rev Clin Immunol 3:531-541 (Pubitemid 47091230)
5. Sarzi-Puttini P, Azteni F, Gerli R et al (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9:849-852
6. Gerli R, Vaudo G, Bocci EB et al (2010) Functional impairment of arterial wall in primary Sjögren's syndrome: combined action of immunological and inflammatory factors. Arthritis Care Res 62:712-718
7. Vaudo G, Bocci EB, Shoenfeld Y et al (2005) Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum 52:3890-3897 (Pubitemid 41798228)
8. Bartoloni E, Shoenfeld Y, Gerli R (2010) Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. doi: 10.1002/acr.20322
9. Bartoloni E, Alunno A, Luccioli F et al (2010) Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Rev Cardiovasc Ther 8:1309-1316
10. Bartoloni E, Alunno A, Bistoni O, Gerli R (2010) How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev 9:701-707
11. Holmqvist ME, Wedrèn S, Jacobsson LT et al (2010) No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis. Results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 60:2861-2869
12. Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54-58 (Pubitemid 36091647)
13. Solomon DH, Goodson NJ, Katz JN et al (2006) Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65:1608-1612 (Pubitemid 44799673)
14. Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325-331
15. Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 69:683-688
16. Metsios G, Stavropoulos-Kalinoglou A, Sandoo A et al (2010) Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Cardiovasc Med J 4:89-96
17. Libby P, Okamoto Y, Rocha V, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213-220
18. Turesson C, Matteson EL (2007) Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 19:190-196 (Pubitemid 46208780)
19. Volkmann ER, Grossman JM, Sahakian LJ et al (2010) Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res 62:258-265
20. McMahon M, Grossman I, Skaggs B et al (2009) Dysfunctional proinflammatory high density lipoproteins confer increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:2428-2437
21. Steiner G, Urowitz M (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Arthritis Rheum 38:372-381
22. Gerli R, Bocci EB, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y (2006) Traditional cardiovascular risk factors in primary Sjögren'syndrome: role of dyslipidemia [letter]. Rheumatology 45:1580-1581 (Pubitemid 44817075)
23. Abeles AM, Pillinger MH (2006) Statins are anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393-407 (Pubitemid 43228614)
24. Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833-1846 (Pubitemid 44574489)
25. Bisoendial RJ, Stroes ES, Kastelein JJ, Tak PP (2010) Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 6:157-164
26. Jick SS, Choi H, Li L, McInnes IB, Sattar N (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68:546-551
27. Paraskevas KI (2008) Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27:281-287
28. McCarey D, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015-2021 (Pubitemid 38781100)
29. Lodi S, Evans SJ, Egger P, Carpenter J (2010) Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 69:85-94
30. Petri M, Kiani AN, Post W et al (2006) Lupus Atherosclerosis Prevention Study (LAPS): randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 54:S520
31. Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460-469
32. Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905-2912 (Pubitemid 47502736)
33. Pérez-De-Lis M, Akasbi M, Sisó A et al (2010) Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 19:941-948
34. Kitas G, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8-14
35. Panoulas VF, Douglas KM, Smith JP et al (2009) Transforming growth factor-beta1 869T/C, but not interleukin-6-174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 48:113-118
36. Panoulas VF, Toms TE, Metsios GS et al (2010) Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate. Atherosclerosis 209:255-260
37. Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN (2010) Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a Greek Cohort Study. J Rheumatol. doi: 10.3899/jrheum.100564
38. Danowski A, Leitão N, de Azevedo M, de Souza Papi JA, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195-1199
39. Flammer AJ, Sudano I, Hermann F et al (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117:2262-2269
40. Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD (2008) Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 67:1646-1647
41. Durán-Barragán S, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS (2008) Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus - results from LUMINA (LIX): a multiethnic US cohort. Rheumatology 47:1093-1096 (Pubitemid 351865941)
42. Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L (2010) The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. doi: 10.1007/s11926-010-0145-7
43. van Halm VP, Peters MJ, Voskuyl AE et al (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Ann Rheum Dis 68:1395-1400
44. Parker B, Bruce IN (2010) The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 36:81-97
45. Sabio JM, Vargas-Hito J, Zamora-Pasadas M et al (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36:2204-2211
46. Shahin D, Eltoraby E, Mesbah A, Houssein M (2010) Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 43:661-665
47. Chung CP, Oeser A, Solus JF et al (2008) Inflammation associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58:2105-2112 (Pubitemid 351988102)
48. Venegas-Pont M, Sartori-Valinotti JC, Maric C et al (2009) Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296:R1282-R1289
49. Zhao W, Thacker SG, Hodgin JB (2009) The peroxisome proliferator- activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 183:2729-2740
50. Kaprove Penn S, Kao AH, Schott LL et al (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136-1142
51. Morris SJ, Wasko MC, Antohe JL et al (2010) Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Rheum. doi: 10.1002/acr.20393
52. Jung H, Bobba R, Su J et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863-868
53. Turesson C, Jacobsson LT, Matteson E (2008) Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 4:605-614
54. del Rincon I, O'Leary DH, Haas RW et al (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 50:3813-3822 (Pubitemid 39643928)
55. Westlake SL, Colebatch AN, Baird J (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49:295-307
56. Hochberg MC, Johnston SS, John AK (2008) The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 24:469-480 (Pubitemid 351294396)
57. Ristic G, Lepic T, Glisic B et al (2010) Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology 49:1076-1081
58. Georgiadis AN, Voulgari PV, Argyropoulou MI et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38:13-19
59. Angel K, Aarrestad Provan S, Lovahl Gulseth H, Mowinckel P, Kvien K, Atar D (2010) Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies. A controlled study. Hypertension 55:333.38
60. Kerekes G, Soltsèz P, Dèr H et al (2009) Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 1173:814-821
61. Gallaraga B, Belch JJ, Pullar T, Ogston S, Khan F (2010) Clinical improvement in rheumatoid arthritis is associated with healthier microvascualr function in patients who respond to antirheumatic therapy. J Rheumatol 37:521-528
62. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193:153-159
63. null T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744-2748 (Pubitemid 38737922)
64. null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher et al. Arthritis Rheum 60:631-632
65. + T cells. Arthritis Rheum 54:3060-3061 (Pubitemid 44497790)
66. Kerekes G, Soltsez P, Der H et al (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis and lipid profile in rheumatoid arthritis. Clin Rheumatol 28:705-710
67. Bruce IN (2005) Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 19:823-838 (Pubitemid 41258585)